aTYR PHARMA INC — Director's Dealing 2023

Nov 13, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2023-11-10

Reporting Person: Shukla Sanjay (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-10	Common Stock	P	1422	$1.138	Acquired	77595	Direct
2023-11-13	Common Stock	P	13578	$1.111	Acquired	91173	Direct

Footnotes

F1: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.13 to $1.14 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

F2: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.09 to $1.13 per share. The reporting
person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full
information regarding the number of shares purchased at each separate price.